Expression of p16 and hTERT protein is associated with the presence of high-risk human papillomavirus in Bowenoid papulosis

Journal of Cutaneous Pathology

Volumn 33, Issue 8, 2006, Pages 551-558

  Liu, Houjun ^a,b   Urabe, Kazunori ^b   Moroi, Yoichi ^b   Yasumoto, Shinichiro ^c   Kokuba, Hisashi ^b   Imafuku, Shinichi ^b   Koga, Tetsuya ^b   Masuda, Teiichi ^b   Aburatani, Hiroyuki ^d   Furue, Masutaka ^b   Tu, Yating ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b KYUSHU UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; PROTEIN E7; PROTEIN P16; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ARTICLE; BOWENOID PAPULOSIS; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DNA PROBE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN CARCINOGENESIS; WART VIRUS;

ADULT; BIOPSY; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TELOMERASE;

EID: 33747042751     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00438.x     Document Type: Article

References (53)

1. Kimura S. Bowenoid papulosis of the genitalia. Int J Dermatol 1982; 21: 432.
2. Schwartz RA, Janniger CK. Bowenoid papulosis. J Am Acad Dermatol 1991; 24 (2 Part 1): 261.
3. Crum CP, Liskow A, Petras P, Keng WC, Frick HC II. Vulvar intraepithelial neoplasia (severe atypia and carcinoma in situ). A clinicopathologic analysis of 41 cases. Cancer 1984; 54: 1429.
4. Lookingbill DP, Kreider JW, Howett MK, Olmstead PM, Conner GH. Human papillomavirus type 16 in bowenoid papulosis, intraoral papillomas, and squamous cell carcinoma of the tongue. Arch Dermatol 1987; 123: 363.
5. Rudlinger R, Grob R, Yu YX, Schnyder UW. Human papillomavirus-35-positive bowenoid papulosis of the anogenital area and concurrent human papillomavirus-35-positive verruca with bowenoid dysplasia of the periungual area. Arch Dermatol 1989; 125: 655.
6. Abdennader S, Lessana-Leibowitch M, Pelisse M. An atypical case of penile carcinoma in situ associated with human papillomavirus DNA type 18. J Am Acad Dermatol 1989; 20 (5 Part 2): 887.
7. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl) 2004; 193: 35. Epub 2003 June 28.
8. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002 Nov; 89 (2): 213-28.
9. Durst M, Glitz D, Schneider A, zur Hausen H. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 1992; 189: 132.
10. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992; 23: 117.
11. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18, E6 proteins with p53. Science 1990; 248: 76.
12. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16, E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934.
13. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999; 18: 7690.
14. Jones DL, Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16, E7 oncoprotein. J Virol 1997; 71: 2905.
15. Scheffner M, Romanczuk H, Munger K, Huibregtse JM, Mietz JA, Howley PM. Functions of human papillomavirus proteins. Curr Top Microbiol Immunol 1994; 186: 83.
16. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704.
17. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995; 375: 506.
18. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995; 375: 503.
19. Nakao Y, Yang X, Yokoyama M, et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997; 75: 1410.
20. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342.
21. Xiong Y, Kuppuswamy D, Li Y, et al. Alteration of cell cycle kinase complexes in human papillomavirus E6- and E7-expressing fibroblasts precedes neoplastic transformation. J Virol 1996; 70: 999.
22. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741.
23. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Immuno-histochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int 1998; 48: 580.
24. Gewin L, Galloway DA. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J Virol 2001; 75: 7198.
25. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79.
26. Veldman T, Horikawa I, Barrett JC, Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol 2001; 75: 4467.
27. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase [see comments]. Science 1997; 276: 561.
28. Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev 1998; 12: 1073.
29. Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 1998; 58: 622.
30. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998; 58: 1558.
31. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life span by introduction of telomerase into normal human cells. Science 1998; 279: 349.
32. Counter CM, Meyerson M, Eaton EN, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit telomerase. Oncogene 1998; 16: 1217.
33. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002; 66: 407.
34. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995; 269: 1236.
35. Baege AC, Berger A, Schlegel R, Veldman T, Schlegel R. Cervical epithelial cells transduced with the papillomavirus E6/E7 oncogenes maintain stable levels of oncoprotein expression but exhibit progressive, major increases in hTERT gene expression and telomerase activity. Am J Pathol 2002; 160: 1251.
36. McMurray HR, McCance DJ. 2003 Human papillomavirus type 16 E6 activates TERTs gene transcription through induction of c-Myc and release of USF-mediated repression. J Virol 2003; 77: 9852.
37. INK4a/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high risk human papillomavirus. J Pathol 2003; 201: 109.
38. Sano T, Sakurai S, Fukuda T, Nakajima T. Unsuccessful effort to detect human papillomavirus DNA in urinary bladder cancers by the polymerase chain reaction and in situ hybridization. Pathol Int 1995; 45: 506.
39. Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003; 201: 535.
40. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276.
41. Olshan AF, Weissler MC, Pei H, et al. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 1997; 14: 811.
42. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin DCDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996; 93: 4350.
43. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994; 54: 6078.
44. Nindl I, Meyer T, Schmook T, et al. Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer. Dermatol Surg 2004; 30: 409.
45. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162: 747.
46. Bibbo M, Klump WJ, DeCecco J, Kovatich AJ. Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol 2002; 46: 25.
47. Wong JM, Kusdra L, Collins K. Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat Cell Biol 2002; 4: 731.
48. Wu A, Ichihashi M, Ueda M. Correlation of the expression of human telomerase subunits with telomerase activity in normal skin and skin tumors. Cancer 1999; 86: 2038.
49. Hu S, Chan HL, Chen MC, Pang JH. Telomerase expression in benign and malignant skin neoplasms: comparison of three major subunits. J Formos Med Assoc 2002; 101: 593.
50. Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003; 24: 1167. Epub 2003 May 22.
51. Snijders PJ, van Duin M, Walboomers JM, et al. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res 1998; 58: 3812.
52. Jeong Seo E, Jung Kim H, Jae Lee C, Tae Kang H, Seong Hwang E. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells. Gynecol Oncol 2004; 94: 40.
53. Ferber MJ, Montoya DP, Yu C, et al. Integrations of the hepatitis B v irus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003; 22: 3813.